Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E10.11 EPS (ttm)28.24 Insider Own0.10% Shs Outstand175.89M Perf Week1.25%
Market Cap50.20B Forward P/E8.67 EPS next Y32.90 Insider Trans0.00% Shs Float175.29M Perf Month1.25%
Income5.42B PEG1.97 EPS next Q7.92 Inst Own92.70% Short Float2.33% Perf Quarter22.99%
Sales14.23B P/S3.53 EPS this Y24.50% Inst Trans-0.67% Short Ratio1.96 Perf Half Y24.57%
Book/sh76.06 P/B3.75 EPS next Y-0.39% ROA20.50% Target Price299.00 Perf Year-10.59%
Cash/sh25.23 P/C11.31 EPS next 5Y5.14% ROE40.10% 52W Range215.77 - 344.00 Perf YTD-5.16%
Dividend- P/FCF7.59 EPS past 5Y22.70% ROI23.60% 52W High-16.10% Beta1.07
Dividend %- Quick Ratio1.70 Sales past 5Y14.20% Gross Margin86.00% 52W Low33.76% ATR9.33
Employees7800 Current Ratio1.90 Sales Q/Q4.70% Oper. Margin47.10% RSI (14)60.17 Volatility2.67% 2.61%
OptionableYes Debt/Eq0.43 EPS Q/Q17.30% Profit Margin37.90% Rel Volume0.69 Prev Close285.40
ShortableYes LT Debt/Eq0.32 EarningsOct 22 BMO Payout0.00% Avg Volume2.08M Price288.61
Recom2.70 SMA20-0.44% SMA5012.93% SMA20015.15% Volume542,667 Change1.12%
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Nov-21-19 11:00AM  Top Health Care Stocks for December 2019 Investopedia
07:30AM  Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder GlobeNewswire
Nov-20-19 03:44PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
03:32PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
07:15AM  Healthcare ETF (RYH) Hits New 52-Week High Zacks
Nov-19-19 11:29AM  Biogen shares rise on patent resolution with Sawai MarketWatch
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
Nov-18-19 10:44AM  Top & Flop ETFs Halfway Through Q4 Zacks
Nov-15-19 04:44AM  Market Morning: Alibaba Goes Hong Kong, Uber Dump, Alzheimers Hope, Cannabis Collapse Market Exclusive
Nov-14-19 03:08PM  Biogen shares fall 3% MarketWatch
01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
12:01PM  Biogen Sheds $3 Billion in Value on Top Drugs Patent Review Bloomberg
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
12:32PM  6 Undervalued Stocks According to the Peter Lynch Value GuruFocus.com
Nov-12-19 11:37AM  Buy Big Biotech But Not Gilead, Analyst Says Barrons.com
09:43AM  Roche's SMA Drug Meets Primary Endpoint in Pivotal Study Zacks
09:00AM  Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's? Investor's Business Daily
07:00AM  Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY PR Newswire
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:03AM  AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL Zacks
03:23AM  UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target Reuters
Nov-08-19 02:58PM  The Unloved Biotechnology ETF Rally ETF Trends
08:24AM  Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out Barrons.com
08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 11:53AM  Biotech Stock On The Radar: Alkermes At A Crossroads Benzinga
Nov-06-19 08:20AM  Biogen ups investment in biosimilars MarketWatch
07:30AM  Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis GlobeNewswire
Nov-05-19 08:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
04:30PM  Biogen to Host Investor Webcasts from Clinical Trials on Alzheimers Disease (CTAD) Congress on December 5, 2019 GlobeNewswire
02:28PM  Sanofi settles 4-year legal battle over Genzyme drug for $315M American City Business Journals
02:24PM  Chinese Regulators Tentatively Approve Novel Alzheimer's Drug The First Since 2003 Benzinga
01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
Nov-01-19 02:16PM  The Good, Bad, and Ugly for Biogen Stock InvestorPlace
11:34AM  Healthcare ETF (IHF) Tops in October: 5 Best Stocks Zacks
06:54AM  How Does Biogen's (NASDAQ:BIIB) P/E Compare To Its Industry, After Its Big Share Price Gain? Simply Wall St.
Oct-31-19 01:57PM  Cramer Makes The Case Why Biogen's Stock Could Double In Value Benzinga
06:52AM  Calculating The Fair Value Of Biogen Inc. (NASDAQ:BIIB) Simply Wall St.
Oct-30-19 10:43AM  Healthcare ETFs Win in October: Here's Why Zacks
10:34AM  Biogens Alzheimers Drug Could Be a Winner. One Analyst Recommends the Bet. Barrons.com
09:13AM  Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts TheStreet.com
08:03AM  UPDATE 2-Small relief for Biogen in MS drug approval Reuters
07:41AM  FDA approves multiple sclerosis drug from Biogen and Alkermes Reuters
07:40AM  Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges MarketWatch
07:30AM  Biogen and Alkermes Announce FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis GlobeNewswire
Oct-29-19 06:41PM  Analysts Like Biogen's Chances of Getting Alzheimer's Drug Approved GuruFocus.com
Oct-28-19 12:46PM  Biogen Alzheimer's Case Shows Danger of Trials Killing Good Drugs GuruFocus.com
11:59AM  Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More Zacks
Oct-25-19 06:23PM  Alzheimer's Drug May Resurrect Biogen's Growth GuruFocus.com
04:19PM  Stock Market Nears Highs; Tesla, Boeing, Nike, Intel, Microsoft, Biogen Are Big Movers: Weekly Review Investor's Business Daily
09:51AM  Biotech Fund Investors Are Fleeing, but Biogen Stock and Others Are Rising Barrons.com
07:00AM  A Biotech Giant Not Named Biogen Also Had a Good Week Bloomberg
06:00AM  FOCUS-Biogen's secret campaign to bring its Alzheimer's drug back from the ashes Reuters
Oct-24-19 11:09AM  The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals Zacks
10:06AM  Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3 Zacks
06:15AM  PMN.TO: The Resurrection of Aducanumab Zacks Small Cap Research
12:31AM  Edited Transcript of BIIB earnings conference call or presentation 22-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
Oct-23-19 02:29PM  Drugmaker Alkermes cuts 160 jobs in effort to lower expenses American City Business Journals
02:00PM  Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? Investor's Business Daily
11:37AM  Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle' Benzinga
10:10AM  Biotech ETFs Surge on a Flurry of Positive News Zacks
09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
09:15AM  Late Selloff Pulls Stocks Lower Zacks
07:53AM  Biogen Alzheimers Revival Wins New Believers, Yet Doubts Linger Bloomberg
07:26AM  Biogens stock blasts off after surprise reversal on Alzheimers drug, earnings beat MarketWatch
06:30AM  Biogen Stock Climbed on Surprise Alzheimers Drug News. The Effects Could Be Lasting. Barrons.com
01:45AM  Biogen, Eisai revive plans for Alzheimer's drug, surprising market Reuters
12:00AM  Alzheimers drug revival gives hope to millions and investors Financial Times
Oct-22-19 09:17PM  FirstFT: Todays top stories Financial Times +26.11%
06:10PM  US Indexes End Lower Tuesday GuruFocus.com
05:10PM  Biogen Stock Rockets On Alzheimer's News, But Nasdaq Hit By More Institutional Selling Investor's Business Daily
04:46PM  US STOCKS-Wall Street slips after rejection of Brexit timetable Reuters
04:21PM  Biogen Stock Rockets On Stunning Reversal In Alzheimer's Treatment Investor's Business Daily
04:13PM  Does Novartis' Gene Therapy Stand A Chance Of Undercutting Biogen? Investor's Business Daily
04:08PM  US Stock Market Overview – Stocks Slip Led Down by Nasdaq; McDonald’s Misses on Top and Bottom Line FX Empire
03:55PM  PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald's Earnings Move Benzinga
03:54PM  Jon Najarian Highlights Unusual Options Activity In Biogen Benzinga
03:33PM  US STOCKS-Mixed earnings, failed Brexit vote push down S&P 500 Reuters
03:01PM  Jim Cramer: The Soundness of My Methods TheStreet.com
01:00PM  Earnings Season Racks Up More Winners and Losers Barrons.com
12:58PM  Biogen Bombshell Triggers Annual-High Options Volume Schaeffer's Investment Research
12:54PM  Biogen resurrects Alzheimer's drug, stock soars Reuters Videos
12:39PM  Biogen Will Take Alzheimer's Therapy to FDA, Reviving Hope Bloomberg
11:48AM  Biogen Stock Could Have Run Up Too Far on Alzheimers Drug Revival Barrons.com
11:43AM  Biogen Alzheimers Drug Far From Done Deal, Wall Street Says Bloomberg
11:26AM  Jim Cramer's Thoughts on Biogen's Alzheimer's Drug TheStreet.com
11:20AM  Biogen's stock surge increases value of recent stock repurchased by over $700 million MarketWatch
10:48AM  Biogen Stock Is Soaring as Hope Returns for Alzheimers Drug Barrons.com
10:40AM  Earnings Data Deluge Zacks
10:23AM  Biogen (BIIB) Up 40% on Alzheimer's Drug & More Zacks
10:11AM  Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab Zacks
10:06AM  Biogen stock surges despite skepticism over Alzheimers drug plan American City Business Journals
09:58AM  Dow Jones Today: Stocks Strengthen As Disney Surges, Netflix Dives On Verizon Deal Investor's Business Daily
09:42AM  Biogen Surges as Momentum for Alzheimers Treatment Revives Hope Bloomberg
09:28AM  Beware Biogens Alzheimers Drug Resurrection Bloomberg
09:06AM  Biogen (BIIB) Q3 Earnings & Sales Beat Estimates Zacks
09:02AM  The Dow Is Drifting, While Biogen Soars After Upbeat Earnings Barrons.com
08:24AM  Biogen shares soar on plan to seek Alzheimers drug approval Financial Times
08:13AM  Biogen's stock soars toward record rally, set to add nearly $17 billion to market cap MarketWatch
08:08AM  Dow Jones Futures: Biogen Soars On Alzheimer's Drug News, McDonald's Earnings Miss Investor's Business Daily
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM